StemRIM

4599

JP3399690001

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-06-03 am EDT			5-day change	1st Jan Change
460 ^JPY	-0.65%		+1.55%	-20.42%

May. 09	StemRIM to Seek Shareholders' Approval on Capital Stock Reduction	MT
Mar. 13	StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy	CI

StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023

June 18, 2023 at 10:30 pm EDT

StemRIM provided earnings guidance for the year ending July 31, 2023. For the period, The company expects operating revenue of Â¥2,350 million, operating income of Â¥146 million, net income of Â¥170 million or Â¥2.84 per share.

Latest news about StemRIM

StemRIM to Seek Shareholders' Approval on Capital Stock Reduction	May. 09	MT
StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy	Mar. 13	CI
StemRIM Inc. Announces Patent Registration for the Use of the HMGB1 Fragment Peptide, as an Additional Therapeutic Indication of Cartilage Disorders	Jan. 31	CI
StemRIM Allocates 300 Stock Options to R&D Partner	Dec. 28	MT
StemRIM to Issue Stock Acquisition Rights	Dec. 13	MT
StemRIM Issues Over 300 Million Yen of Shares as Restricted Stock Compensation	Dec. 06	MT
StemRIM Enters into Contract for Implementation of Phase 2 Investigator-Initiated Clinical Trial Targeting Ischemic Cardiomyopathy Using Redasemtide, in Collaboration with Osaka University Hospital and Shionogi & Co	Dec. 04	CI
StemRIM Issues 433,000 Shares as Restricted Stock Compensation	Nov. 17	MT
StemRIM, Shiseido, Osaka University Extend Skin Aging Research Collaboration	Nov. 17	MT
StemRIM Discloses Issuance Details of Stock Options to Directors	23-09-20	MT
Stemrim Inc. Announces Patent Registration (Us) for the Use of the Hmgb1 Fragment Peptide, Redasemtide	23-09-06	CI
StemRIM Announces Patent Registration for the Use of Redasemtide as an Additional Treatment for Cardiomyopathy and Old Myocardial Infarction	23-09-04	CI
StemRIM Inc. Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide Targeting Acute Ischemic Stroke	23-07-31	CI
StemRIM Inc. Announces Commencement of Global Late Phase 2 Clinical Trial for Redasemtide in Patients with Acute Ischemic Stroke in the Europe and China	23-07-25	CI
StemRIM Inc. Announces Patent Registration for the Use of the Hmgb1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction	23-07-18	CI
StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023	23-06-18	CI
StemRIM Inc. Announces Publication of Scientific Articles for Stem Cell Gene Therapy	23-05-16	CI
StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke	23-04-28	CI
StemRIM Bags 450 Million Yen Milestone Payment From Shionogi; Details FY23 Earnings Outlook, Liver Disease Trial Results	23-04-12	MT
Stemrim Inc. Announces Commencement of Global Phase II Trial of Redasemtide in Patients with Acute Ischemic Stroke	23-04-10	CI
Toyo Suisan Kaisha, Ltd. Revises Earnings Guidance for the Year 2023	23-04-10	CI
StemRIM(TSE:4599) added to S&P Global BMI Index	20-09-21	CI
Shionogi & Co., Ltd. Enters into a New License Agreement with StemRIM	20-06-30	CI
Certain Shares of StemRIM are subject to a Lock-Up Agreement Ending on 4-FEB-2020.	20-02-03	CI
StemRIM Announces Earnings Results for the Quarter Ended October 31, 2019; Provides Earnings Guidance for the Full Year Ending July 31, 2020	19-12-11	CI

Chart StemRIM

Duration

Period

More charts

Company Profile

StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Companyâs main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.

Sector

Pharmaceuticals

Calendar

2024-06-11 - Q3 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for StemRIM

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
STEMRIM	-20.42%	181M
CSL LIMITED	-1.85%	89.87B
SAMSUNG BIOLOGICS CO.,LTD.	-3.95%	37.57B
UCB	+61.72%	26.47B
BIOMARIN PHARMACEUTICAL INC.	-22.14%	14.25B
INCYTE CORPORATION	-7.96%	12.99B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.33%	11.93B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-46.33%	10.84B
SWEDISH ORPHAN BIOVITRUM AB	+4.27%	9.11B
INNOVENT BIOLOGICS, INC.	-19.53%	7.32B

Biopharmaceuticals

StemRIM

Equities

4599

JP3399690001

Pharmaceuticals

StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023

Latest news about StemRIM

Chart StemRIM

Company Profile

Income Statement Evolution

Ratings for StemRIM

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals